Nucor Corporation vs BIO-TECHNE Corp — how do they compare? Nucor Corporation trades at $251.87 (market cap $55.84B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Nucor Corporation is far larger — about 4.9× BIO-TECHNE Corp's market cap, and Nucor Corporation pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and BIO-TECHNE Corp for 63 Days on average.
| NUE | TECH | |
|---|---|---|
Market Cap | $55.84B | $11.36B |
Volume | 848,835 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $72.61 |
52-Week Low | $131.78 | $43.31 |
Typical Hold Time | 78 Days | 63 Days |
Enterprise Value | $60.25B | $11.39B |
Dividend Yield | 0.91% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $250.98, up 1.84% on the day, showing resilience amid a mixed technical backdrop. Recent earnings have beaten expectations in Q1 and Q2 2026, though Q4 2025 was a miss. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% for 2025, and analyst consensus is a Moderate Buy with a $266.88 price target. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%.
The outlook for NUE is cautiously optimistic, supported by earnings beats and a solid dividend history, but risks include competitive pressures from new steel capacity and volatile steel prices. The stock's current valuation metrics, such as a P/E of 19.64, appear reasonable relative to historical performance, offering potential upside if earnings guidance is met.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Trailing returns across standard periods
Latest headlines on both assets
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →